Vip Viprakasit

List of Publications by Year
in descending order

128 papers	2,239 citations	257450 24 h-index	265206 42 g-index
129 all docs	129 docs citations	129 times ranked	1910 citing authors

#	Article	IF	Citations
1	Hb H disease: clinical course and disease modifiers. Hematology American Society of Hematology Education Program, 2009, 2009, 26-34.	2.5	140
2	Clinical Classification, Screening and Diagnosis for Thalassemia. Hematology/Oncology Clinics of North America, 2018, 32, 193-211.	2.2	123
3	Changing patterns in the epidemiology of Î²â€thalassemia. European Journal of Haematology, 2020, 105, 692-703.	2.2	122
4	Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with Î² thalassemia. Blood, 2004, 103, 3296-3299.	1.4	102
5	A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies?. Blood Reviews, 2018, 32, 300-311.	5.7	95
6	Clinical features and molecular analysis in Thai patients with HbH disease. Annals of Hematology, 2009, 88, 1185-1192.	1.8	91
7	Mutations in KrÃ¼ppel-like factor 1 cause transfusion-dependent hemolytic anemia and persistence of embryonic globin gene expression. Blood, 2014, 123, 1586-1595.	1.4	76
8	Treating iron overload in patients with nonâ€transfusionâ€dependent thalassemia. American Journal of Hematology, 2013, 88, 409-415.	4.1	67
9	Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload. Blood, 2015, 125, 3868-3877.	1.4	67
10	Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Annals of Hematology, 2013, 92, 1485-1493.	1.8	64
11	Iron chelation therapy in the management of thalassemia: the Asian perspectives. International Journal of Hematology, 2009, 90, 435-445.	1.6	61
12	Prevalence and distribution of iron overload in patients with transfusionâ€dependent anemias differs across geographic regions: results from the <scp>CORDELIA</scp> study. European Journal of Haematology, 2015, 95, 244-253.	2.2	61
13	Clinical phenotypes and molecular characterization of Hb H-PaksÃ© disease. Haematologica, 2002, 87, 117-25.	3.5	58
14	Deferiprone (GPOâ€Lâ€ONE^{Â®}) monotherapy reduces iron overload in transfusionâ€dependent thalassemias: 1â€year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPOâ€Lâ€ONE; A001) from Thailand. American Journal of Hematology, 2013, 88, 251-260.	4.1	43
15	Iron overload across the spectrum of nonâ€transfusionâ€dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions. British Journal of Haematology, 2017, 176, 288-299.	2.5	43
16	Paper-based microchip electrophoresis for point-of-care hemoglobin testing. Analyst, The, 2020, 145, 2525-2542.	3.5	39
17	Hb H hydrops fetalis syndrome associated with the interaction of two common determinants of Î± thalassaemia (–MED /Î±TSaudi Î±). British Journal of Haematology, 2002, 117, 759-762.	2.5	38
18	A Normal Reference of Bone Mineral Density (BMD) Measured by Dual Energy X-Ray Absorptiometry in Healthy Thai Children and Adolescents Aged 5â€“18 Years: A New Reference for Southeast Asian Populations. PLoS ONE, 2014, 9, e97218.	2.5	38

#	Article	IF	Citations
19	De novo deletion within the telomeric region flanking the human Î± globin locus as a cause of Î± thalassaemia. British Journal of Haematology, 2003, 120, 867-875.	2.5	36
20	Detection of cardiac iron overload with native magnetic resonance T1 and T2 mapping in patients with thalassemia. International Journal of Cardiology, 2017, 248, 421-426.	1.7	31
21	Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially under-recognised condition. Orphanet Journal of Rare Diseases, 2014, 9, 131.	2.7	30
22	Co-inheritance of Hb Pak Num Po, a novel ?1 gene mutation, and ?0 thalassemia associated with transfusion-dependent Hb H disease. American Journal of Hematology, 2004, 75, 157-163.	4.1	28
23	Revisiting the nonâ€transfusionâ€dependent (NTDT) vs. transfusionâ€dependent (TDT) thalassemia classification 10 years later. American Journal of Hematology, 2021, 96, E54-E56.	4.1	28
24	Utility of labile plasma iron and transferrin saturation in addition to serum ferritin as iron overload markers in different underlying anemias before and after deferasirox treatment. European Journal of Haematology, 2016, 96, 19-26.	2.2	27
25	Complex interactions of deltabeta hybrid haemoglobin (Hb Lepore-Hollandia) Hb E (beta26 GA) and alpha+ thalassaemia in a Thai family. European Journal of Haematology, 2002, 68, 107-111.	2.2	25
26	Problems in determining thalassemia carrier status in a program for prevention and control of severe thalassemia syndromes: a lesson from Thailand. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1605-1614.	2.3	24
27	Optimising iron chelation therapy with deferasirox for non-transfusion-dependent thalassaemia patients: 1-year results from the THETIS study. Blood Cells, Molecules, and Diseases, 2016, 57, 23-29.	1.4	24
28	Children with hemoglobin E/Î²â€thalassemia have a high risk of being vitamin D deficient even if they get abundant sun exposure: A study from thailand. Pediatric Blood and Cancer, 2013, 60, 1683-1688.	1.5	22
29	Quality of life in patients with Î²â€thalassemia: A prospective study of transfusionâ€dependent and nonâ€transfusionâ€dependent patients in Greece, Italy, Lebanon, and Thailand. American Journal of Hematology, 2019, 94, E261-E264.	4.1	21
30	Effect ofNUDT15on incidence of neutropenia in children with acute lymphoblastic leukemia. Pediatrics International, 2019, 61, 754-758.	0.5	21
31	Hb G-MAKASSAR [Î²6(A3)Gluâ†'Ala; CODON 6 (GACâ†'GCG)]: MOLECULAR CHARACTERIZATION, CLINICAL, AND HEMATOLOGICAL EFFECTS. Hemoglobin, 2002, 26, 245-253.	0.8	20
32	Serum ferritin in the diagnosis of cardiac and liver iron overload in thalassaemia patients realâ€world practice: a multicentre study. British Journal of Haematology, 2018, 182, 301-305.	2.5	19
33	A prospective analysis for prevalence of complications in Thai nontransfusionâ€dependent Hb E/Î²â€thalassemia and Î±â€thalassemia (Hb H disease). American Journal of Hematology, 2018, 93, 623-629.	4.1	18
34	COMPOUND HETEROZYGOSITY FORÎ±⁰-THALASSEMIA (â^'â^'^{THAI}) AND Hb CONSTANT SPRING CAUSES SEVERE Hb H DISEASE. Hemoglobin, 2002, 26, 155-162.	0.8	17
35	Adrenal insufficiency is prevalent in HbE/Î²â€thalassaemia paediatric patients irrespective of their clinical severity and transfusion requirement. Clinical Endocrinology, 2013, 79, 776-783.	2.4	17
36	Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias. Blood Transfusion, 2013, 11, 108-22.	0.4	17

#	Article	IF	Citations
37	Prevalence and predictors of cardiac and liver iron overload in patients with thalassemia: A multicenter study based on real-world data. Blood Cells, Molecules, and Diseases, 2017, 66, 24-30.	1.4	16
38	Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes. Drug Design, Development and Therapy, 2016, Volume 10, 4073-4078.	4.3	15
39	Estimating the burden of Î±-thalassaemia in Thailand using a comprehensive prevalence database for Southeast Asia. ELife, 2019, 8, .	6.0	15
40	Clinical Presentation and Molecular Identification of Four Uncommon Alpha Globin Variants in Thailand. Acta Haematologica, 2014, 131, 88-94.	1.4	14
41	Development of a new disease severity scoring system for patients with non-transfusion-dependent thalassemia. European Journal of Internal Medicine, 2016, 28, 91-96.	2.2	14
42	<scp>MRI</scp> for the diagnosis of cardiac and liver iron overload in patients with transfusionâ€dependent thalassemia: An algorithm to guide clinical use when availability is limited. American Journal of Hematology, 2018, 93, E135-E137.	4.1	14
43	Serum ferritin values between 300 and 800 ng/mL in nontransfusionâ€dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. American Journal of Hematology, 2017, 92, E35-E37.	4.1	13
44	Prevalence of low bone mass among adolescents with nontransfusionâ€dependent hemoglobin E/Î²â€thalassemia and its relationship with anemia severity. Pediatric Blood and Cancer, 2018, 65, e26744.	1.5	13
45	Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in Î²-thalassemia: current evidence and future clinical development. Expert Review of Hematology, 2021, 14, 633-644.	2.2	13
46	Improving outcomes and quality of life for patients with transfusion-dependent Î²-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology, 2021, 14, 897-909.	2.2	13
47	Twice daily deferasirox significantly improves clinical efficacy in transfusion dependent thalassaemias who were inadequate responders to standard once daily dose. Blood Cells, Molecules, and Diseases, 2013, 51, 96-97.	1.4	12
48	Acute haemolytic crisis in a Thai patient with homozygous haemoglobin Constant Spring (Hb CS/CS): a case report. Annals of Tropical Paediatrics, 2004, 24, 323-328.	1.0	11
49	Prevalence of HFE mutations among the Thai population and correlation with iron loading in haemoglobin E disorder*. European Journal of Haematology, 2004, 73, 43-49.	2.2	11
50	Clinical efficacy and safety evaluation of tailoring iron chelation practice in thalassaemia patients from Asia-Pacific: a subanalysis of the EPIC study of deferasirox. International Journal of Hematology, 2011, 93, 319-328.	1.6	11
51	The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 163-163.	1.4	11
52	Baseline levels of plasma endothelin-1 (ET-1) and changes during transfusion in thalassemic patients. American Journal of Hematology, 2002, 70, 260-262.	4.1	10
53	Two independent origins of Hb Dhonburi (Neapolis) [Î² 126 (H4) Valâ†'Gly]: An electrophoretically silent hemoglobin variant. Clinica Chimica Acta, 2007, 376, 179-183.	1.1	10
54	Human primary erythroid cells as a more sensitive alternative in vitro hematological model for nanotoxicity studies: Toxicological effects of silver nanoparticles. Toxicology in Vitro, 2015, 29, 1982-1992.	2.4	10

#	Article	IF	Citations
55	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. American Journal of Hematology, 2017, 92, 1356-1361.	4.1	10
56	Haematological effects of oral administration of bitopertin, a glycine transport inhibitor, in patients with nonâ€transfusionâ€dependent Î²â€thalassaemia. British Journal of Haematology, 2021, 194, 474-477.	2.5	10
57	Severe neonatal haemolytic anaemia caused by compound heterozygous KLF1 mutations: report of four families and literature review. British Journal of Haematology, 2021, 194, 626-634.	2.5	9
58	Dinucleotide deletion in -Î±3.7 allele causes a severe form of Î±+ thalassaemia. European Journal of Haematology, 2003, 71, 133-136.	2.2	8
59	An overview of current treatment strategies for Î²-thalassemia. Expert Opinion on Orphan Drugs, 2014, 2, 665-679.	0.8	8
60	Iron chelation therapy for non-transfusion-dependent thalassemia (NTDT): A status quo. Blood Cells, Molecules, and Diseases, 2014, 52, 88-90.	1.4	8
61	Longitudinal Effect of Luspatercept Treatment on Iron Overload and Iron Chelation Therapy (ICT) in Adult Patients (Pts) with Î²-Thalassemia in the Believe Trial. Blood, 2020, 136, 47-48.	1.4	8
62	Sustained Reductions in Red Blood Cell (RBC) Transfusion Burden and Events in Î²-Thalassemia with Luspatercept: Longitudinal Results of the Believe Trial. Blood, 2020, 136, 45-46.	1.4	8
63	Continued Improvement and Normalization of Myocardial T2* In Patients with Î²-thalassemia Major Treated with Deferasirox (ExjadeÂ®) for up to 3 Years. Blood, 2010, 116, 4276-4276.	1.4	8
64	Prevalence of left ventricular diastolic dysfunction by cardiac magnetic resonance imaging in thalassemia major patients with normal left ventricular systolic function. BMC Cardiovascular Disorders, 2019, 19, 245.	1.7	7
65	Development of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 171-176.	4.1	7
66	Validation of a patientâ€reported outcomes symptom measure for patients with nontransfusionâ€dependent thalassemia (NTDTâ€PRO^{Â©}). American Journal of Hematology, 2019, 94, 177-183.	4.1	7
67	Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatrics International, 2021, 63, 404-409.	0.5	7
68	INVASIVE FUNGAL INFECTION IN CHILDREN WITH ACUTE LEUKEMIA AND SEVERE APLASTIC ANEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021039.	1.3	7
69	Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial. Blood, 2019, 134, 2245-2245.	1.4	7
70	Health-Related Quality of Life Outcomes for Patients with Transfusion-Dependent Beta-Thalassemia Treated with Luspatercept in the Believe Trial. Blood, 2020, 136, 8-9.	1.4	7
71	Unusual phenotype of Hemoglobin EE with Hemoglobin H disease: a pitfall in clinical diagnosis and genetic counseling. Journal of Pediatrics, 2004, 144, 391-393.	1.8	6
72	A Rare Association of Î±0-Thalassemia (â€“ â€“SEA) and an Initiation Codon Mutation (ATGâ†'A-G) of the Î±2 Gene Causes Hb H Disease in Thailand. Hemoglobin, 2005, 29, 235-240.	0.8	6

#	Article	IF	Citations
73	Variable Genotype-Phenotype Correlations in Patients With a Rare Nondeletional Î±-thalassemia; Hb Pak		

#	Article	IF	Citations
91	Deferasirox Continues to Reduce Iron Overload in Non-Transfusion-Dependent Thalassemia: A One-Year, Open-Label Extension to a One-Year, Randomized, Double-Blind, Placebo-Controlled Study (THALASSA). Blood, 2012, 120, 3258-3258.	1.4	3
92	Identification of optimal thalassemia screening strategies for migrant populations in Thailand using a qualitative approach. BMC Public Health, 2021, 21, 1796.	2.9	3
93	Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood, 2020, 136, 30-32.	1.4	3
94	The origin of sickle cell disease in Thailand. International Journal of Laboratory Hematology, 2019, 41, e13-e16.	1.3	2
95	Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusionâ€dependent thalassemia. Pediatric Blood and Cancer, 2020, 67, e28483.	1.5	2
96	Clinical outcomes and prognosis of Thai retinoblastoma patients. Pediatrics International, 2021, 63, 671-677.	0.5	2
97	Feasibility of and barriers to thalassemia screening in migrant populations: a cross-sectional study of Myanmar and Cambodian migrants in Thailand. BMC Public Health, 2021, 21, 1177.	2.9	2
98	An urgent need for improving thalassemia care due to the wide gap in current real-life practice and clinical practice guidelines. Scientific Reports, 2021, 11, 13283.	3.3	2
99	Serum Ferritin, Labile Plasma Iron and Transferrin Saturation: Comparison Between Underlying Anemias with Transfusional Iron Overload Before and After Treatment with Deferasirox.. Blood, 2012, 120, 2126-2126.	1.4	2
100	Knowledge, Cultural, and Structural Barriers to Thalassemia Screening in Migrant Populations in Thailand. Blood, 2018, 132, 2228-2228.	1.4	2
101	An Unexpectedly High Frequency of Sptb Gene Mutation (SPTB exon 29: c.6055T>C (p.Ser2019Pro;) Tj ETQq1 1 0.784314 rgBT /Ove Against Malarial Pressure. Blood, 2018, 132, 2322-2322.	1.4	2
102	LONG-TERM EFFECTIVENESS, SAFETY, AND TOLERABILITY OF TWICE-DAILY DOSING WITH DEFERASIROX IN CHILDREN WITH TRANSFUSION-DEPENDENT THALASSEMIAS UNRESPONSIVE TO STANDARD ONCE-DAILY DOSING. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021065.	1.3	2
103	Allele related mutation specific-polymerase chain reaction for rapid diagnosis of Hb New York (beta) Tj ETQq1 1 0.784314 rgBT /Overlo Chotmaihet Thangphaet, 2002, 85 Suppl 2, S558-63.	0.1	2
104	An openâ€label, multicenter, efficacy, and safety study of deferasirox in ironâ€overloaded patients with nonâ€transfusionâ€dependent thalassemia (<scp>THETIS</scp>): 5â€year results. American Journal of Hematology, 2022, 97, .	4.1	2
105	Hb Woodville, a rare alpha-globin variant, caused by codon 6 mutation of the alpha1 gene. European Journal of Haematology, 2006, 76, 79-82.	2.2	1
106	Co-inheritance of Southeast Asian Ovalocytosis (SAO) and G6PD deficiency associated with acute hemolysis in a Thai patient. Blood Cells, Molecules, and Diseases, 2019, 79, 102347.	1.4	1
107	An integration-free iPSC line (MUSIi008-A) derived from a patient with severe hemolytic anemia carrying compound heterozygote mutations in KLF1 gene for disease modeling. Stem Cell Research, 2019, 34, 101344.	0.7	1
108	Antifungal Prophylaxis with Posaconazole versus Fluconazole in Children with Neutropenia Following Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. Journal of Blood Medicine, 2021, Volume 12, 679-689.	1.7	1

#	Article	IF	Citations
109	An automated liver segmentation in liver iron concentration map using fuzzy c-means clustering combined with anatomical landmark data. BMC Medical Imaging, 2021, 21, 138.	2.7	1
110	Identification of a Novel IL7RA Mutation (444_450insA) Caused Marked Reduction in CD127 Expression from a Cohort Molecular Analysis of Severe Combined Immunodeficiency (Tâˆ', B+, NK+ SCID) in Thailand.. Blood, 2006, 108, 1247-1247.	1.4	1
111	Randomized Phase II Study Evaluating the Efficacy and Safety of Deferasirox in Non-Transfusion-Dependent Thalassemia Patients with Iron Overload.. Blood, 2009, 114, 5111-5111.	1.4	1
112	Epigenetic Analysis of Beta-Globin Gene Cluster during Hematopoiesis.. Blood, 2008, 112, 1863-1863.	1.4	1
113	Improvement in Right Ventricular Function Following 1 Year of Deferasirox Therapy in Patients with Î²-Thalassemia.. Blood, 2009, 114, 5106-5106.	1.4	1
114	Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias. Blood, 2010, 116, 4272-4272.	1.4	1
115	Quality of Life in Patients with Î²-Thalassemia: Transfusion Dependent Versus Non-Transfusion Dependent. Blood, 2017, 130, 751-751.	1.4	1
116	A Phase 2a Study Evaluating the Safety and Pharmacokinetics (PK) of Luspatercept in Pediatric Patients with Transfusion-Dependent Î²-Thalassemia (TDT). Blood, 2021, 138, 4161-4161.	1.4	1
117	Durability of Hemoglobin Response and Reduction in Transfusion Burden Is Maintained over Time in Patients with Pyruvate Kinase Deficiency Treated with Mitapivat in a Long-Term Extension Study. Blood, 2021, 138, 848-848.	1.4	1
118	Hematological parameters and red blood cell indices in healthy Thai children: a revision for 2005. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2005, 88 Suppl 8, S188-96.	0.1	1
119	Crushed deferasirox <scp>filmâ€coated</scp> tablets in pediatric patients with transfusional hemosiderosis: Results from a <scp>singleâ€arm</scp>, interventional phase 4 study (<scp>MIMAS</scp>). American Journal of Hematology, 2022, 97, .	4.1	1
120	Recent Advances in Molecular Understanding of NTDT: 2012. Thalassemia Reports, 2013, 3, e13.	0.5	0
121	Genetic Modifiers in Î²-Thalassemia. Hemoglobin, 2019, 43, 304-304.	0.8	0
122	Safety, Tolerability and Dose Response of FBS0701, a Novel Iron Chelator for Treatment of Transfusional Iron Overload: Results of a 24-Week Multicenter, International Phase 2 Study. Blood, 2011, 118, 690-690.	1.4	0
123	Twice Daily Dosing of Deferasirox Significantly Improves Clinical Efficacy in Transfusion Dependent Thalassemias Who Were Inadequate Responders to Standard Once Daily Dose. Blood, 2012, 120, 1026-1026.	1.4	0
124	"Huthal": A Survey of North American, Indian and Thai Hematologists Regarding Hydroxyurea Use in Thalassemia. Blood, 2014, 124, 4036-4036.	1.4	0
125	Long Term Efficacy, Safety and Tolerability (>24 Months) of Twice Daily Dosing of Deferasirox in Transfusion Dependent Thalassemias Who Were Unresponsive to Standard Once Daily Dose. Blood, 2015, 126, 958-958.	1.4	0
126	A Longitudinal Study in Elderly Patients with Non-Transfusion Dependent Thalassemia (NTDT) Emphasizes the Size of Splenomegaly Predicts Transfusion Requirement Later in Life. Blood, 2019, 134, 2250-2250.	1.4	0

#	Article	IF	Citations
127	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. Blood, 2021, 138, 3074-3074.	1.4	0
128	Bone mineral density in primarily preadolescent children with hemoglobin EÎ²â€thalassemia with different severities and transfusion requirements. Pediatric Blood and Cancer, 0, , .	1.5	0